Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | STING1 | Q86WV6 | 11/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | HINT1 | P49773 | 2/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16490098 | 1.00 | ADORA3 (0.50) | ADORA3STING1PDE3BPDE3AHINT1 | |
| SCHEMBL20879383 | 1.00 | ADORA3 (0.50) | ADORA3STING1PDE3BPDE3AHINT1 | |
| SCHEMBL15052858 | 1.00 | ADORA3 (0.50) | ADORA3STING1PDE3BPDE3AHINT1 | |
| SCHEMBL26793927 | 1.00 | ADORA3 (0.50) | ADORA3STING1PDE3BPDE3AHINT1 | |
| SCHEMBL15052857 | 1.00 | ADORA3 (0.50) | ADORA3STING1PDE3BPDE3AHINT1 | |
| SCHEMBL17641512 | 0.90 | ADORA3 (0.54) | ADORA3STING1PDE3BPDE3AHINT1 | |
| SCHEMBL15070301 | 0.89 | HPGD (0.41) | ADORA3STING1PDE3BPDE3AHINT1 | |
| SCHEMBL15966105 | 0.85 | STING1 (0.49) | ADORA3STING1PDE3BPDE3AHINT1 | |
| SCHEMBL16144340 | 0.84 | ADORA3 (0.53) | ADORA3STING1PDE3BPDE3AHINT1 | |
| SCHEMBL23520033 | 0.83 | ADORA3 (0.55) | ADORA3STING1PDE3BPDE3AHINT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160331770-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2016-11-17 | — | — | US | disclosed |
| WO-2014209979-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160331770-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | ADORA3 59/4885STING1 301/4885PDE3B 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.